Title [Korea Patent Award] GENUV 2020-07-18

GENUV established "ATRIVIEWTM", a screening platform using neural stem cells for the identification of substances that provide a neuroprotective and differentiating effect on neurons. Through this screening technology, GENUV succeeded in discovering a small molecule ‘repurposed’ drug candidate, SNR 1611, that shows efficacy in neurogenesis and neural homeostasis recovery.





GENUV has begun a phase 1/2a clinical trial on its Amyotrophic Lateral Sclerosis (ALS) drug candidate, SNR1611, in Korea.  Samsung Medical Center, Yonsei Severance Hospital, Seoul Asan Medical Center and Korea University Anam Hospital initiated the recruitment of patient and the first patient was enrolled on June 24, 2020.




To view original article, please click here.

Prev [Hidden Champions on the Move] GENUV reports continued progress in Lou Gehrig’s Drug Clinical Trial
Next GENUV to commence P1/2a Clinical Trial for ALS Drug which Shows Efficacy in Neurogenesis and Neural Homeostasis Recovery